Abstract
We analysed the spectrum of microbial agents causing bronchial-pulmonary complications in 52 patients who underwent various surgical interventions and were supported by long-term artificial ventilation of lungs. “FarGALS”, a medication with high antimicrobial activity developed and produced at V.Vakhidov Republican Specialised Centre of Surgery, was used for the first time in the nebuliser therapy. In comparison with other antimicrobial agents, the use of “FarGALS” has reduced complications of long-period artificial ventilation, justifying further investigations of this medication for the use in nebuliser therapy by intensive care units (ICU).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Skyler JS, Weinstock RS, Pascin P, Yale JF, Barrett E, Gerich JE, Gerstein HC (2005) Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects A 16-month randomized, comparative trial. Diab Care 28(7):1630–1635
Frutos-Vivar F, Esteban A (2003) When to wean from a ventilator: an evidence-based strategy. Cleve Clin J Med 70(5):383–398
Cook D (2000) Ventilator-associated pneumonia: perspectives on the burden illness. Intensive Care Med 26(S1):31–37
MacIntyre NR, Cook DJ, Ely WE, Epstein SK, Fink JB, Heffner JE, Hess D, Hubmayer RD, Scheinhorn DJ (2001) Evidence-based guidelines for weaning and discontinuing ventilatory support. Chest 120(6):375–395
Kollef MH (2000) Ventilator-associated pneumonia: the importance of initial empiric antibiotic selection. Infect Med 17:278–283
Bajenov LG, Mustamov AN, Ekubjanov FT, Bajenova SS, Shanieva ZA (2008) Antimicrobal activity of the new biotechnological drug - ForGALS and its clinical use. Bull Int Sci Surg Assoc 3(1):23–25
Smaldone GC, McKenzie J, Cruz-Rivera M, Hoag JE (2000) Budesonide inhalation suspension is chemically compatible with other nebulizing formulations. Chest 118(4):98S
Boe J, Dennis JH, Driscoll BR (2001) European Respiratory Society guidelines on the use of nebulizers. Eur Respir J 18:228–242
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this paper
Cite this paper
Nazirov, F.G. et al. (2011). New Anti-Microbial Treatment of Purulent-Inflammatory Lung Diseases in Patients Supported by Long-Term Artificial Ventilation of Lungs. In: Mikhalovsky, S., Khajibaev, A. (eds) Biodefence. NATO Science for Peace and Security Series A: Chemistry and Biology. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0217-2_26
Download citation
DOI: https://doi.org/10.1007/978-94-007-0217-2_26
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-0216-5
Online ISBN: 978-94-007-0217-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)